# Treeline Biosciences

> Treeline Biosciences is a Watertown, Massachusetts biotech founded in 2021 by Loxo Oncology founder Josh Bilenker and former Novartis oncology head Jeff Engelman. It pairs in-house wet-lab R&D with leading-edge computational tools to invent cancer medicines reliably and repeatedly, choosing targets by what the technology can reach rather than by therapeutic fashion. After operating largely in stealth, Treeline has raised more than $1.1 billion and moved three programs - a BCL6 degrader, a pan-KRAS inhibitor, and an EZH2 inhibitor - into Phase 1 trials. In June 2026 it agreed to go public through an all-stock reverse merger with Standard BioTools, with the combined company set to trade on Nasdaq as 'TRLN'.

- **Founded:** 2021
- **Headquarters:** Watertown, Massachusetts, United States
- **Founders:** Josh Bilenker (Co-Founder & CEO), Jeff Engelman (Co-Founder & Chief Scientific Officer)
- **Team size:** ~200 employees
- **Products:** TLN-121, TLN-372, TLN-254, Integrated discovery engine
- **Notable:** Raised more than $1.1 billion, largely in stealth, since founding in 2021., Advanced three internally and externally sourced programs into Phase 1 trials simultaneously (BCL6, KRAS, EZH2)., Built fully in-house discovery operations across Watertown, San Diego, and Basel.

## Products & services

- **TLN-121** — Internally developed BCL6 degrader in Phase 1 trials for B-cell and T-cell lymphomas.
- **TLN-372** — Internally developed pan-KRAS inhibitor in Phase 1 trials for solid tumors carrying certain KRAS mutations.
- **TLN-254** — EZH2 inhibitor in Phase 1 trials for T-cell lymphomas, licensed from Jiangsu Hengrui Pharmaceuticals in 2023.
- **Integrated discovery engine** — A fully in-house platform combining wet-lab medicinal chemistry, structural biology, and computational/AI tools to select and pursue targets based on technological reach rather than a single modality or therapeutic area.

## Achievements

- Raised more than $1.1 billion, largely in stealth, since founding in 2021.
- Advanced three internally and externally sourced programs into Phase 1 trials simultaneously (BCL6, KRAS, EZH2).
- Built fully in-house discovery operations across Watertown, San Diego, and Basel.
- Founded by the team behind Loxo Oncology, which produced three FDA-approved medicines before its $8B acquisition by Eli Lilly.
- Agreed in June 2026 to reach the public markets via reverse merger at a ~$2.5B implied valuation.

## Latest updates

- **2026-06** — Announced a definitive all-stock reverse merger with Standard BioTools; combined company to trade on Nasdaq as 'TRLN' and operate as Treeline Biosciences, expected to close in H2 2026 with over $900M cash.
- **2025-09** — Unveiled its first three clinical candidates and closed a $200M Series A extension, bringing total funding past $1.1B.
- **2026** — Expects initial Phase 1 data and plans to file an IND for a fourth program, with three more programs in oncology, neurology, and immunology slated for 2027-2028.

## Links

- Website: https://treeline.bio
- LinkedIn: https://www.linkedin.com/company/treeline-biosciences
- Twitter/X: https://twitter.com/treelinebio

---

Profile page: https://yespress.io/treeline
Published by YesPress — https://yespress.io
Last updated: 2026-06-10